碘对比剂短缺期间卒中血管影像的最佳实践建议
本文基于2022年碘对比剂全球短缺背景,由单一综合卒中中心多学科工作组制定卒中患者CT血管成像、CT灌注成像及数字减影血管造影的使用参数与本地指南,提出「最佳实践」建议供其他医院系统参考,以维持高质量卒中诊疗。
要点
- 多学科工作组快速制定本地指南以应对碘对比剂短缺。
- 为卒中患者的CTA、CTP和DSA使用设定参数与推荐。
- 建议可作为其他医院应对供应链问题的蓝图。
局限性
- 建议来自单一中心,可能不适用于所有医院系统。
- 未报告具体患者数据或临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
GE Healthcare© announced on April 19, 2022, that their main factory and distributor of iodinated contrast had experienced a temporary shutdown because of COVID-19 outbreak in Shanghai, China. This, along with other supply chain issues, led to a worldwide shortage of iodinated contrast agents, Omnipaque and Visipaque. Our Comprehensive Stroke Center was confronted with the cascading effect of this iodinated contrast material shortage. We took immediate steps to revise our protocols and processes to continue to provide high-quality care to our stroke patients. A multidisciplinary working group comprised of representatives of our stroke center, including vascular neurology, diagnostic neuroradiology, and neurovascular surgery, urgently met to brainstorm how to mitigate the shortage. We established parameters and local guidelines for the use of CT angiography, CT perfusion, and digital subtraction angiography for stroke patients. In this article, we propose "best practice" recommendations from a single Joint Commission approved Comprehensive Stroke Center that can be used as blueprint by other hospital systems when navigating potential future supply chain issues, to provide consistent high-quality stroke care.
引用
- Bhole, Solenski, Donahue, et al. Best Practice Recommendations for Stroke Vascular Imaging During Iodinated Contrast Shortage. Neurol Clin Pract. 2023. PMID: 37064591. doi:10.1212/CPJ.0000000000200119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。